Reduction of MUC6 Expression Enhances Esophageal Epithelial Barrier Function and Suppresses Epithelial-Mesenchymal Transition in Reflux Esophagitis - Report - MDSpire

Reduction of MUC6 Expression Enhances Esophageal Epithelial Barrier Function and Suppresses Epithelial-Mesenchymal Transition in Reflux Esophagitis

  • By

  • Xue Jia

  • Ying Zhao

  • Hongrui Li

  • Shuaishuai Fan

  • Haiqing Hu

  • January 22, 2026

  • 0 min

Share

Reduction of MUC6 Expression Enhances Esophageal Epithelial Barrier Function

Overview

This study demonstrates that downregulation of MUC6 expression improves esophageal epithelial barrier function and reduces epithelial-mesenchymal transition in patients with reflux esophagitis (RE). The findings suggest MUC6 as a potential biomarker and therapeutic target for RE management.

Background

Reflux esophagitis (RE) is a chronic inflammatory condition linked to gastroesophageal reflux disease (GERD), which can lead to severe complications, including esophageal cancer. Current treatment options primarily involve medications and surgical interventions, but the rising incidence of RE highlights the need for novel biomarkers for early diagnosis and treatment. MUC6, a mucin implicated in esophageal diseases, has shown dysregulation in RE, warranting further investigation.

Data Highlights

GroupMUC6 Expression
RE PatientsElevated
Non-RE PatientsNormal

Key Findings

  • MUC6 expression is significantly elevated in esophageal tissues of RE patients compared to non-RE patients.
  • Downregulation of MUC6 enhances esophageal epithelial barrier function.
  • Reduction of MUC6 expression suppresses epithelial-mesenchymal transition in RE.
  • Clinical samples were collected from 25 RE patients and 25 non-RE patients for analysis.
  • Findings suggest MUC6 could serve as a promising target for RE diagnosis and treatment.

Clinical Implications

The study indicates that targeting MUC6 expression may improve treatment outcomes for patients with reflux esophagitis. Clinicians should consider the potential of MUC6 as a biomarker for early diagnosis and as a therapeutic target in managing RE.

Conclusion

The reduction of MUC6 expression presents a novel approach to enhancing esophageal barrier function and mitigating disease progression in reflux esophagitis. Further research is warranted to explore MUC6's role in clinical practice.

References

  1. Author(s)/Org, Source, Year -- Title
  2. Journal of Crohn's and Colitis — Epithelial genetic muscarinic receptor 3 ablation induces sex-specific modulation of colonic intestinal progenitor cells and response to intestinal injury
  3. Journal of Crohn's and Colitis — The Intestinal Mucin Isoform Landscape Reveals Region-Specific Biomarker Panels for Inflammatory Bowel Disease Patient Stratification
  4. the new gastroenterologist — Sequential endoscopy may boost GERD control
  5. Updates in Surgery — Evaluating Nocturnal Baseline Impedance and Endoscopic Mucosal Impedance in Eosinophilic Esophagitis Patients: A Novel Approach for Monitoring and Treatment?
  6. Sequential endoscopy may boost GERD control
  7. ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
  8. Vonoprazan (VOQUEZNA)

Original Source(s)

Reduction of MUC6 Expression Enhances Esophageal Epithelial Barrier Function and Suppresses Epithelial-Mesenchymal Transition in Reflux Esophagitis

  • by Xue Jia, Ying Zhao, Hongrui Li, Shuaishuai Fan, Haiqing Hu

  • January 22, 2026

Related Content

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
The pathogenesis and surgical treatment progress of gastroesophageal reflux disease